ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3672
-0.0208 (-5.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3880
Open0.3996
Bid0.0000 x 800
Ask0.0000 x 1000
Day's Range0.3420 - 0.4180
52 Week Range0.2700 - 1.2200
Volume635,115
Avg. Volume210,555
Market Cap24.724M
Beta (3Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1090
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.95
Trade prices are not sourced from all markets
  • IsoRay (ISR) Reports Q2 Loss, Tops Revenue Estimates
    Zacks7 days ago

    IsoRay (ISR) Reports Q2 Loss, Tops Revenue Estimates

    IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 8.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press7 days ago

    IsoRay: Fiscal 2Q Earnings Snapshot

    The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.9 million in the period. In the final minutes of trading on ...

  • GlobeNewswire8 days ago

    Isoray Announces Second Quarter Fiscal 2019 Financial Results

    Record Revenue and Gross ProfitRevenue Increased 24% Year-Over-Year RICHLAND, Wash., Feb. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and.

  • ACCESSWIRE8 days ago

    IsoRay, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 12, 2019 / IsoRay, Inc. (NYSEMKT: ISR ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on February 12, 2019 at 4:30 PM Eastern ...

  • IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks15 days ago

    IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire21 days ago

    Isoray To Announce Second Quarter Fiscal 2019 Financial Results on February 12, 2019

    RICHLAND, WASH., Jan. 30, 2019 --  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.

  • GlobeNewswire22 days ago

    Medical University of South Carolina Performs World’s First Prostate Cancer Surgery Using Blu Build Brachytherapy System

    Dr. David T. Marshall, a professor of Radiation Oncology and Urology, and medical director of the Clinical Trials Office at the Hollings Cancer Center, performed the surgery on October 26, 2018. “No two patients are exactly alike.

  • GlobeNewswire3 months ago

    IsoRay Names Jonathan Hunt New Chief Financial Officer

    Hunt has more than 25 years of finance and accounting experience excelling as a versatile leader with a successful track record in turnarounds, startups, mergers, divestitures, growth strategies, performance and operations management and analysis at a number of organizations, including Fortune 500 companies. “We are excited to have Jonathan back at IsoRay. Before joining IsoRay, Hunt was Chief Financial Officer at Vivid Learning Systems, where he had a central role in the company’s turnaround, that included growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the company.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Micron Solutions, Gentherm, ENSERVCO, IsoRay, Trilogy Metals, and Xtant Medical — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
    Zacks3 months ago

    IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates

    IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -9.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    IsoRay: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of ...

  • Associated Press5 months ago

    IsoRay: Fiscal 4Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 4 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. For the year, the company ...

  • When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?
    Simply Wall St.5 months ago

    When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?

    IsoRay Inc’s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength
    Simply Wall St.5 months ago

    What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength

    The direct benefit for IsoRay Inc (NYSEMKT:ISR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • ACCESSWIRE7 months ago

    Free Technical Research on IsoRay and Three More Medical Supplies Equities

    On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).

  • ACCESSWIRE7 months ago

    Today's Research Reports on Stocks to Watch: Staffing 360 Solutions and IsoRay

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.

  • IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy
    Market Realist7 months ago

    IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy

    Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.